基于胱抑素C、乳酸、白介素-6和NT-proBNP的CLIP评分用于急性心肌梗死后心源性休克死亡风险评估
该研究基于CULPRIT-SHOCK试验458例急性心肌梗死合并心源性休克患者,开发了仅含胱抑素C、乳酸、白介素-6和NT-proBNP四种生物标志物的CLIP评分用于预测30天死亡。评分在内部验证、内部-外部时间验证及IABP-SHOCK II试验163例外部队列中校准良好,C统计量分别为0.82、0.82和0.73,且优于SAPS II和IABP-SHOCK II评分。
要点
- CLIP评分仅用四种生物标志物预测心梗后心源性休克30天死亡,外部验证C统计量0.73。
- CLIP评分区分度优于SAPS II(0.83 vs 0.62,P<0.001)和IABP-SHOCK II评分(0.83 vs 0.76,P=0.03)。
- 该评分或可作为心源性休克早期风险分层与决策辅助工具。
核心结论
- 基于胱抑素C、乳酸、白介素-6和NT-proBNP四种生物标志物的CLIP评分可用于急性心肌梗死后心源性休克患者30天死亡风险分层,并在多个队列中验证校准良好。
研究设计与样本
- 研究基于随机对照CULPRIT-SHOCK试验中458例急性心肌梗死合并心源性休克患者开发30天死亡预后模型,采用惩罚多变量逻辑回归筛选预测因子并估计系数。
- 模型在CULPRIT-SHOCK试验内部及内部-外部时间验证,并在随机对照IABP-SHOCK II试验163例心源性休克患者中进行外部验证,血样于随机化时采集。
主要发现
- 从58个候选变量中筛选出30天死亡最强的四个预测因子——胱抑素C、乳酸、白介素-6和NT-proBNP,构成CLIP评分。
- CLIP评分内部验证C统计量0.82(95%CI 0.78-0.86),内部-外部时间验证C统计量0.82(95%CI 0.75-0.89),外部验证C统计量0.73(95%CI 0.65-0.81)。
- CLIP评分预后区分度优于SAPS II(0.83 vs 0.62,P<0.001)和IABP-SHOCK II风险评分(0.83 vs 0.76,P=0.03)。
临床怎么用
- 对于急性心肌梗死后心源性休克患者,可考虑早期检测胱抑素C、乳酸、白介素-6和NT-proBNP以计算CLIP评分,辅助30天死亡风险分层和临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cardiogenic shock (CS) complicating acute myocardial infarction (AMI) still reaches excessively high mortality rates. This analysis is aimed to develop a new easily applicable biomarker-based risk score. METHODS AND RESULTS: A biomarker-based risk score for 30-day mortality was developed from 458 patients with CS complicating AMI included in the randomized CULPRIT-SHOCK trial. The selection of relevant predictors and the coefficient estimation for the prognostic model were performed by a penalized multivariate logistic regression analysis. Validation was performed internally, internally externally as well as externally in 163 patients with CS included in the randomized IABP-SHOCK II trial. Blood samples were obtained at randomization. The two trials are registered with ClinicalTrials.gov (NCT01927549 and NCT00491036), are closed to new participants, and follow-up is completed. Out of 58 candidate variables, the four strongest predictors for 30-day mortality were included in the CLIP score (cystatin C, lactate, interleukin-6, and N-terminal pro-B-type natriuretic peptide). The score was well calibrated and yielded high c-statistics of 0.82 [95% confidence interval (CI) 0.78-0.86] in internal validation, 0.82 (95% CI 0.75-0.89) in internal-external (temporal) validation, and 0.73 (95% CI 0.65-0.81) in external validation. Notably, it outperformed the Simplified Acute Physiology Score II and IABP-SHOCK II risk score in prognostication (0.83 vs 0.62; P < 0.001 and 0.83 vs. 0.76; P = 0.03, respectively). CONCLUSIONS: A biomarker-only score for 30-day mortality risk stratification in infarct-related CS was developed, extensively validated and calibrated in a prospective cohort of contemporary patients with CS after AMI. The CLIP score outperformed other clinical scores and may be useful as an early decision tool in CS.
引用
- Ceglarek U, Schellong P, Rosolowski M, et al. The novel cystatin C, lactate, interleukin-6, and N-terminal pro-B-type natriuretic peptide (CLIP)-based mortality risk score in cardiogenic shock after acute myocardial infarction. Eur Heart J. 2021. PMID: 33647946. doi:10.1093/eurheartj/ehab110
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。